Rechanneling the Current Cardiac Risk Paradigm: Arrhythmia Risk Assessment During Drug Development Without the Thorough QT Study
July 23, 2013
Silver Spring, Maryland, USA
The mission of the HESI Cardiac Safety Committee is to improve public health by reducing unanticipated cardiovascular-related adverse effects from drugs or chemicals, and to develop innovative approaches to support early detection and prediction as well as improved understanding of cardiovascular toxicology and pathobiology.
The HESI Cardiac Safety Committee is excited to announce the winners for the committee’s new Early Career Seminar Award Series. This award offers an opportunity for postdocs and early career scientists to share their research, learn from, and network with experts in the toxicology and safety pharmacology fields from academia, regulatory agencies, and pharmaceutical companies. Awardees receive a $500 USD award and are invited to present their research on a public webinar with Cardiac Safety Committee members and other invited guests.
Three awardees were selected for this inaugural Seminar Series:
This group is working to understand and characterize use of stem cell–derived cardiomyocytes in cardiac safety assessments. An article that included best practices for use of stem cell cardiomyocytes in cardiac safety assessments was published in Regulatory Toxicology and Pharmacology. A new group is planning a study to explore in vitro assay ability to detect cardiotoxicity.
Leadership Team:
Ksenia Blinova, PhD (US Food and Drug Administration)
Godfrey Smith, PhD (University of Glasgow)
HESI Staff:
Jennifer Pierson, MPH
This working group is dedicated to investigating mechanisms of proarrhythmic risk. They continue to collaborate with the CiPA Initiative and ICH, and recently published its anticipated high throughput systems (HTS) ion channel work. A new subteam is scoping a conduction/ sodium channel paper to discuss the history and challenges surrounding this topic.
A 3-phased project was conducted by the HESI Pro-Arrhythmia Working Group starting with a detailed literature review and followed by a collaborative HESI-FDA database of 150 new drug candidates to evaluate how predictive nonclinical studies are to clinical outcomes.
Leadership Team:
Jose Vicente Ruize, PhD (US Food and Drug Administration)
Jean-Pierre Valentin, PhD (UCB Biopharma)
HESI Staff:
Jennifer Pierson, MPH
This working group has examined the sensitivity within a preclinical species to assess the function of contractility. They continue their partnership with University of Surrey and Imperial College London on a mathematical model to predict blood pressure changes. The Implanted Telemetry Subteam explored the impact of telemetry lead placement in toxicology studies (a collaboration with the Pro-Arrhythmia Working Group).
Leadership Team:
Michael Pugsley, PhD (Cytokinetics)
Sandy Eldridge, PhD (National Cancer Institute)
HESI Staff:
E’Lissa Flores, PhD
This working group is dedicated to investigating preclinical cardiac biomarkers of hypercoagulability induced under a thrombotic state, in both normal and diseased states. A manuscript was submitted detailing a study investigating the effects of doxorubicin in Zucker diabetic fatty rats. A new study is in the planning stages using xenobiotics to induce the procoagulant state and confirm measurements of biomarkers of interest.
Leadership Team:
Eric Schultze, PhD (Eli Lilly & Company)
Marjory Brooks, DVM (Cornell University)
HESI Staff:
E’Lissa Flores, PhD
The Cardiac Safety Steering Team established this new subteam in early 2020 to develop and provide a structured resource for use when identifying compounds appropriate in a planned committee study. Delivery of this publicly accessible database is anticipated by the end of 2022.
HESI Staff:
Jennifer Pierson, MPH
This subteam was organized in May 2020 in response to the ongoing pandemic. Subteam members identified that emerging treatments for the novel coronavirus may have cardiotoxicities. The group is exploring how to gather cardiac safety data on five emerging therapies, whether prospective or retrospective, and develop a publication.
HESI Staff:
Jennifer Pierson, MPH
Associate Director for Program Development & Resourcing
jpierson@hesiglobal.orgNational Institute of Environmental Health Sciences, National Toxicology Program
US Food and Drug Administration
July 23, 2013
Silver Spring, Maryland, USA
March 18, 2013 – March 19, 2013
Cambridge, Massachusetts, USA
This workshop was co-sponsored by co-sponsored by the HESI Cardiac Safety Technical Committee and the Safety Pharmacology Society.
October 4, 2012
Phoenix, Arizona, USA
This event was sponsored by the HESI Technical Committee on Cardiac Safety.
October 6, 2008 – October 7, 2008
Washington, DC, USA
This event was sponsored by the HESI Cardiac Safety Committee.
September 22, 2008 – September 25, 2008
Madison, Wisconsin, USA
The HESI Cardiac Safety Technical Committee presented gave two presentations (“A HESI Consortium Approach to Assess the Human Predictive Value of Non-Clinical Repolarization Assays") at this event.
February 14, 2008 – February 15, 2008
Washington, DC, USA
This workshop was sponsored by the HESI Biomarkers of Toxicity Committee.
Regulatory Toxicology and Pharmacology, 2013
Cardiovascular (CV) safety concerns are a significant source of drug development attrition in the pharmaceutical industry today.
Journal of Pharmacological and Toxicological Methods, 2006
Drugs that delay cardiac repolarization pose potential safety risks to patients and cause serious regulatory concern because of the link between QT interval prolongation and the potentially fatal arrhythmia torsades de pointes (TdP).
British Journal of Pharmacology, 2008
Knowledge of the cardiac safety of emerging new drugs is an important aspect of assuring the expeditious advancement of the best candidates targeted at unmet medical needs while also assuring the safety of clinical trial subjects or patients.
British Journal of Pharmacology, 2015
Evaluating whether a new medication prolongs QT intervals is a critical safety activity that is conducted in a sensitive animal model during non-clinical drug development.
Science Translational Medicine, 2016
Advances in cancer therapy has resulted in more cancer survivors, and now quality of life throughout treatment and surviving years is becoming a new focus for the scientific community. There are often unintended toxicities related to cancer therapies. HESI established the THRIVE program to address quality-of-life research.
Journal of Pharmacological and Toxicological Methods, 2019
Voltage-sensitive optical (VSO) sensors offer a minimally invasive method to study the time course of repolarization of the cardiac action potential (AP). This Comprehensive in vitro Proarrhythmia Assay (CiPA) cross-platform study investigates protocol design and measurement variability of VSO sensors for ...
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.